On September 6, 2022 Almac Sciences, a member of the Almac Group, and University College Dublin (UCD), reported that they have been awarded a Science Foundation Ireland (SFI) ‘Frontiers for the Future’ grant (Press release, Almac, SEP 6, 2022, View Source [SID1234619013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The €420,000 grant will enable the exploitation, for the first-time, of emerging enzymes such as ene-reductase (ERED) and carboxylic acid reductase (CAR) enzymes in continuous flow reactors to develop new routes to chemical products. Almac Sciences and UCD will work together to establish the use of enzymatic multi-step reactions in continuous flow reactors as readily and widely applicable tools for the sustainable synthesis of fine chemicals.

The project team, co-funded by Almac Sciences, will include one postdoctoral researcher and two PhD studentships over the next 4 years based primarily in UCD. Both PhD students, Ruairi Bannon and Philip Jamieson, have undertaken industry placements within Almac as part of their undergraduate studies. The placement has equipped them with key transferable skills and valuable insights into critical decision-making for flow processes with industrial relevance.

Lead academic at UCD, Dr Marcus Baumann said "This project will further build on our existing collaboration with Almac Sciences, strengthening expertise for continuous flow within Ireland with a focus on enhancing the application of continuous flow within the biocatalysis sphere."

Almac and UCD have collaborated on various projects over the last few years and have recently been awarded SSPC’s Industry Impact of the Year, recognising their joint development of continuous flow processes using enzymes.

Almac continues to enhance its flow service offering with a completed £500,000 investment to date already in place. This project further establishes Almac Sciences in the field of flow chemistry and builds on novel methodologies applicable for industrial scale transformations.

Dr Megan Smyth, Team Leader Custom and Flow Chemistry, Almac Sciences commented: "Collaborations such as these established with Marcus and UCD are of the utmost importance to us in Almac Sciences. By supporting development of students, we can ensure a pipeline of expertly trained flow chemists in line with our growing capabilities. For Ruairi and Philip, the opportunity to avail of expertise at Almac Sciences and UCD fosters key interdisciplinary skills and research excellence in the area of flow. I am excited to work closely with them both throughout their studies and wish them every success."

On September 6, 2022Takara Bio Europe (TBE) reported a partnership with the German company BioeXsen GmbH for the distribution of in vitro diagnostic solutions for the qPCR detection of common pathogens found in respiratory tract infections (Press release, Takara Bio, SEP 6, 2022, View Source [SID1234619033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Respiratory tract infections are associated with high morbidity and mortality worldwide, and their symptoms may not point to a single diagnosis. In such cases, a rapid and accurate pathogen diagnosis is essential for appropriate treatment.

BioeXsen has been one of the leading suppliers of RT-qPCR kits during the Covid-19 pandemic. The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio’s enzymes. Combining Takara Bio’s renowned expertise in molecular biology with BioeXsen GmbH’s state-of-the-art clinical solutions, the in vitro diagnostic medical devices detect more than 20 pathogens.

Ranging from the detection of the novel coronavirus (SARS-CoV-2) to multiplexed detection of 24 pathogens in a syndromic panel, these CE-IVD kits’ simple yet efficient protocols have been tested and validated on commonly used instruments and can accommodate a wide range of samples, with an optimized turnaround time of 29 to 60 minutes. These efficient and significant solutions have already been used for more than 200 million tests worldwide, proving their versatility and suitability for all laboratories.

"At Takara Bio, we strongly believe that high-performing technologies are the keystone to accurate diagnosis" says Pierre Lacaze, Managing Director at TBE. "Since the beginning of the Covid-19 pandemic, we have been committed to supplying robust enzymes and supporting our customers to develop and optimize their diagnostic solutions. We are proud to take another step forward in our partnership with BioeXsen GmbH to distribute a broad portfolio of vital in vitro diagnostic medical devices for infectious diseases."

Klaus Skripalle, Managing Director of BioeXsen GmbH, added, "The synergistic combination of Takara Bio’s reliable enzymes and the cutting-edge technology here at BioeXsen GmbH will result in both higher specificity and increased sensitivity. This alliance provides us with enzymes of better calibre to our previous existing products, allowing us to increase our strength further, which is particularly pertinent at this critical time. As we have all learned during the pandemic, early diagnosis reduces the risk of hospitalization, decreases drug use, and minimizes the risk of death."

With the distribution of these kits, Takara Bio Europe is proud to continue providing essential tools in the fight against COVID-19 and related diseases.

On September 6, 2022 Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that it will present at the H.C. Wainwright 24TH Annual Global Investment Conference, which is taking place September 12-14, 2022 (Press release, Corvus Pharmaceuticals, SEP 6, 2022, View Source [SID1234619050]). The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 12.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Attendees can register to view the webcast here. A webcast of the presentation will be available via the investor relations section of the Corvus website for 90 days following the event.

On September 6, 2022 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022 (Press release, Protara Therapeutics, SEP 6, 2022, View Source [SID1234619068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The prerecorded presentation will become available on-demand on Monday, September 12, 2022 at 7:00 a.m. ET and can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived for 90 days following the presentation.

On September 6, 2022 ADC Therapeutics SA (NYSE: ADCT) reported that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET (Press release, ADC Therapeutics, SEP 6, 2022, View Source [SID1234619085]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.